Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Algorithms
CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study
November 5th, 2007
CNS Response, Inc. (BULLETIN BOARD: CNSO) announced that it has conducted a quality assurance analysis of its current multi-center trial of rEEGSM -guided pharmacotherapy for individuals with treatment-resistant depression. Based on the evaluation, CNS Response is amending the design of the study in order to address issues related to functionality and operability. Changes to the trial design will include (i) un-blinding the treatment physicians, (ii) incorporating the STAR*D treatment algorithm instead of the Texas Medication Algorithm Project (TMAP) as a comparative measure against which rEEGSM will be evaluated, and, (iii) modifying the inclusion criteria of the trial...
Source: Health & Medicine Week (2007-11-05)
|
